MCLEAN, Va. and BUDAPEST, Hungary, June 12 /PRNewswire/ -- Genetic
Immunity, a US/Hungarian clinical-stage Company focused on the development
of its patented nanomedicines for targeted immune amplification, announced
today that the Company will be presenting at the 2008 Bio International
Convention to be held June 17-20, 2008 at the San Diego Convention Center
in San Diego, CA. The Company's President and Chief Executive Officer, Dr.
Julianna Lisziewicz, is scheduled to present at the following times:
-- Wednesday, May 18 at 2:00 p.m. (PT): Dr. Lisziewicz will present an
overview of Genetic Immunity's nanomedicine technology platform and
clinical programs on as part of the infectious disease tract in room
-- Thursday, June 19th at 2:00 p.m. (PT): Dr. Lisziewicz will represent
Genetic Immunity in an international case study, "Biotechnology in
Hungary: Mission Possible," in room 26 AB.
For more information on this event please visit: http://www.bio2008.org.
While at the conference Genetic Immunity will discuss three partnering opportunities. The first is focused on DermaVir Patch, which is the Company's lead nanomedicine candidate for the treatment for HIV/AIDS. This topically delivered nanomedicine is designed to amplify HIV-specific memory T cell responses in order to kill HIV-infected cells specifically while leaving the healthy cells intact.
The second opportunity is DermaPrep, which is a novel and proprietary medical device that supports the topical delivery of macromolecules to lymph nodes. DermaPrep is designed to mimic the body's response and has demonstrated proof of concept with through development of the DermaVir Patch.
The third partnering option is the Company's patented NanoComp nanoformulation technology that includes disease-specific, plasmid DNA-encoded antigens. It is designed to improve the immunigenicity of antigens and induce effective immune responses. NanoComp has also demonstrated proof of concept with the DermaVir Patch, which includes HIV-specific plasmid DNA encoded antigens.
About Genetic Immunity(R)
Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical company establishing leadership in Nanomedicines for targeted immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. The Company aims to discover, develop and commercialize topically administered nanomedicines that can create new markets for treating infectious diseases, cancer and allergies. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. The DermaVir Patch, Genetic Immunity's lead nanomedicine candidate, is in Phase II clinical development and could be the first nanomedicine immune therapy for HIV-infected individuals. The DermaVir Patch has demonstrated excellent safety, immunogenicity and antiviral efficacy in preclinical studies. Phase I/II trials to date have confirmed safety and tolerability and indicate the induction of long-lasting HIV-specific memory T cells.
About the Nanomedicine Technology Platform
Genetic Immunity's nanomedicine immune amplification platform
technology is comprised of two principal components: NanoComp and
DermaPrep. NanoComp is a patented nanoformulation technology that includes
disease-specific plasmid DNA encoded antigens. DermaPrep is the topical
administration device that delivers NanoComp into a patient's lymph node
dendritic cells to induce T cell mediated immune responses that can treat a
broad spectrum of diseases. These two components together make up the
DermaVir Patch. The plasmid DNA within DermaVir Patch's NanoComp
nanoparticles is specific to HIV and topically delivered via DermaPrep to
amplify the immune system to kill only HIV-infected cells.
The Ruth Group
|SOURCE Genetic Immunity|
Copyright©2008 PR Newswire.
All rights reserved